Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab With or Without Tremelimumab as Neoadjuvant Therapy in Resectable Head and Neck Cancer
NCT03737968Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Jan 2019
- Primary completion
- Oct 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Durvalumab monotherapy Arm with Durvalumab + tremelimumab combination therapy Arm (2 arms). Primary endpoints: Locoregional Relapse Rate up to 2 years and Distant Metastatic Rate up to 2 years. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03737968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737968.